1
|
Daban A, Gonnin C, Phan L, Saldmann A, Granier C, Lillo-Lelouet A, Le Beller C, Pouchot J, Weiss L, Tartour E, Fabre E, Medioni J, Oudard S, Vano YA, Dragon-Durey MA, Simonaggio A. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs). Oncoimmunology 2023; 12:2204754. [PMID: 37187974 PMCID: PMC10177742 DOI: 10.1080/2162402x.2023.2204754] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 03/15/2023] [Accepted: 04/16/2023] [Indexed: 05/17/2023] Open
Abstract
INTRODUCTION Immune checkpoint inhibitors (ICIs) are now standard of care in many cancers. They can generate immune-related adverse events (irAEs), but no biomarkers are available to identify patients who are more likely to develop irAEs. We assess the association between pre-existing autoantibodies and occurrence of irAEs. PATIENTS AND METHODS We prospectively collected data from consecutive patients receiving ICIs for advanced cancers, in a single center between May 2015 and July 2021. Autoantibodies testing was performed before ICIs initiation including AntiNeutrophil Cytoplasmic Antibodies, Antinuclear Antibodies, Rheumatoid Factor anti-Thyroid Peroxidase and anti-Thyroglobulin. We analyzed the associations of pre-existing autoantibodies with onset, severity, time to irAEs and with survival outcomes. RESULTS Of the 221 patients included, most had renal cell carcinoma (n = 99; 45%) or lung carcinoma (n = 90; 41%). Grade ≥2 irAEs were more frequent among patients with pre-existing autoantibodies: 64 (50%) vs. 20 (22%) patients (Odds-Ratio= 3.5 [95% CI=1.8-6.8]; p < 0.001) in the positive vs negative group, respectively. irAEs occurred earlier in the positive group with a median time interval between ICI initiation and irAE of 13 weeks (IQR = 8.8-21.6) vs. 28.5 weeks (IQR=10.6-55.1) in the negative group (p = 0.01). Twelve patients (9.4%) experienced multiple (≥2) irAEs in the positive group vs. 2 (2%) in the negative group (OR = 4.5 [95% CI: 0.98-36], p = 0.04). After a median follow-up of 25 months, median PFS and OS were significantly longer among patients experiencing irAE (p = 0.00034 and p = 0.016, respectively). CONCLUSION The presence of pre-existing autoantibodies is significantly associated with the occurrence of grade ≥2 irAEs, with earlier and multiple irAEs in patients treated with ICIs.
Collapse
Affiliation(s)
- A Daban
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France
| | - C Gonnin
- Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France
| | - L Phan
- ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie; Hǒpital Européen Georges Pompidou, AP-HP. Centre – Université Paris Cité, Paris, France
| | - A Saldmann
- Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France
| | - C Granier
- Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France
- INSERM U970, PARCC, Université Paris-Cité, Paris, France
| | - A Lillo-Lelouet
- Department of Pharmacovigilance, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France
| | - C Le Beller
- Department of Pharmacovigilance, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France
| | - J Pouchot
- Department of Internal Medicine, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France
| | - l Weiss
- Department of Clinical Immunology, Hôpital Hôtel-Dieu, AP-HP.Centre – Université Paris Cité, Paris, France
| | - E Tartour
- Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France
- INSERM U970, PARCC, Université Paris-Cité, Paris, France
| | - E Fabre
- INSERM U970, PARCC, Université Paris-Cité, Paris, France
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France
| | - J Medioni
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France
| | - S Oudard
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France
- INSERM U970, PARCC, Université Paris-Cité, Paris, France
| | - YA Vano
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France
- Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, France
| | - MA Dragon-Durey
- Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France
- Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, France
| | - A. Simonaggio
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France
| |
Collapse
|
2
|
Li C, Brasseur G, Granier C, Sofiev M, Timmermans R, Basart S, Pfister G, Kumar R, Caillard B, Boose Y. Introduction to the AQ-WATCH Project and the AQ-WATCH Toolkit to fight air pollution. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac131.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
WHO states that 9 out of 10 persons in the world do not breath clean air and 8 million people die prematurely from air pollution each year. The problem is well understood, but actions to mitigate it are lacking. The purpose of the EU-funded AQ-WATCH Project is precisely to develop effective tools based on the most advanced science technologies to help decision-makers in government and the private sector to address air pollution issues in regions of the world where they operate.
Objectives
AQ-WATCH aims to develops a supply chain to generate innovative downstream products for improving air quality forecasts and attribution based on existing space/in-situ observations to improve public health and to optimize renewable energy in regions of the world. The project consortium includes research and business-oriented partners, who brings together the required expertise to define the optimal functionalities of these products to bring them to the market.
Results
The AQ-WATCH products are organized into 5 modules: (1) Air quality atlas, (2) Air quality attribution & mitigation, (3) Dust and fire forecast, (4) Fracking analysis, and (5) Air quality forecast. They are developed for 3 target regions (Beijing, Colorado and Santiago de Chile) and are integrated into a unified user-interface, the AQ-WATCH Toolkit. Product developers and prime users in the target regions are constantly interacting, and the user feedback is collected, analyzed and included during the product development.
Conclusions
Collaborative work done in AQ-WATCH shows strategic interaction between our research and business-oriented partners. Contributions from local parties are proven to be valuable for regional adaption of the products. A throughout dissemination including regional workshops is essential to ensure proper knowledge uptake by the target audience. Constant exchange with the private sector is required for a smooth transfer from scientific results to commercialized marketable products.
Key messages
• The AQ-WATCH Project follows EU’s initiative to utilize its space observations with added values to develop easily-accessible tools to fight air pollution applicable to regions of the world.
• The AQ-WATCH Toolkit is developed with iterative feedback exchanges between product developers and local users to address air pollution issues, and will be eventually exploited to the market.
Collapse
Affiliation(s)
- C Li
- Environmental Modeling, Max Planck Institute for Meteorology , Hamburg, Germany
| | - G Brasseur
- Environmental Modeling, Max Planck Institute for Meteorology , Hamburg, Germany
- Atmospheric Chemistry Observations and Modeling, National Center for Atmospheric Research , Boulder, USA
| | - C Granier
- Laboratoire d'Aérologie, CNRS-Université de Toulouse , Toulouse, France
- NOAA Chemical Sciences Laboratory, CIRES, University of Colorado , Boulder, USA
| | - M Sofiev
- Atmospheric Composition Modelling Group, Finnish Meteorological Institute , Helsinki, Finland
| | - R Timmermans
- Climate, Air and Sustainability Department, The Netherlands Organisation for Applied Scientific Research , Utrecht, Netherlands
| | - S Basart
- EaAtmospheric Composition Group, Barcelona Supercomputing Centre , Barcelona, Spain
| | - G Pfister
- Atmospheric Chemistry Observations and Modeling, National Center for Atmospheric Research , Boulder, USA
| | - R Kumar
- Atmospheric Chemistry Observations and Modeling, National Center for Atmospheric Research , Boulder, USA
| | - B Caillard
- INERIS DEVELOPPEMENT SAS , Verneuil-en-Halatte, France
| | - Y Boose
- BreezoMeter Ltd , Haifa, Israel
| |
Collapse
|
3
|
Granier C, Borgogno D, Comisso L, Grasso D, Tassi E, Numata R. Marginally stable current sheets in collisionless magnetic reconnection. Phys Rev E 2022; 106:L043201. [PMID: 36397597 DOI: 10.1103/physreve.106.l043201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 09/27/2022] [Indexed: 06/16/2023]
Abstract
Noncollisional current sheets that form during the nonlinear development of spontaneous magnetic reconnection are characterized by a small thickness, of the order of the electron skin depth. They can become unstable to the formation of plasmoids, which allows the magnetic reconnection process to reach high reconnection rates. In this work, we investigate the marginal stability conditions for the development of plasmoids when the forming current sheet is purely collisionless and in the presence of a strong guide field. We analyze the geometry that characterizes the reconnecting current sheet, and what promotes its elongation. Once the reconnecting current sheet is formed, we identify the regimes for which it is plasmoid unstable. Our study shows that plasmoids can be obtained, in this context, from current sheets with an aspect ratio much smaller than in the collisional regime, and that the plasma flow channel of the marginally stable current layers maintains an inverse aspect ratio of 0.1.
Collapse
Affiliation(s)
- C Granier
- Université Côte d'Azur, CNRS, Observatoire de la Côte d'Azur, Laboratoire J. L. Lagrange, Boulevard de l'Observatoire, CS 34229, 06304 Nice Cedex 4, France
- Istituto dei Sistemi Complessi - CNR and Dipartimento di Energia, Politecnico di Torino, Torino 10129, Italy
| | - D Borgogno
- Istituto dei Sistemi Complessi - CNR and Dipartimento di Energia, Politecnico di Torino, Torino 10129, Italy
| | - L Comisso
- Department of Astronomy and Columbia Astrophysics Laboratory, Columbia University, New York, New York 10027, USA
| | - D Grasso
- Istituto dei Sistemi Complessi - CNR and Dipartimento di Energia, Politecnico di Torino, Torino 10129, Italy
| | - E Tassi
- Université Côte d'Azur, CNRS, Observatoire de la Côte d'Azur, Laboratoire J. L. Lagrange, Boulevard de l'Observatoire, CS 34229, 06304 Nice Cedex 4, France
| | - R Numata
- Graduate School of Information Science, University of Hyogo, Kobe 650-0047, Japan
| |
Collapse
|
4
|
Granier C, Gey A, Roncelin S, Weiss L, Paillaud E, Tartour E. Immunotherapy in older patients with cancer. Biomed J 2020; 44:260-271. [PMID: 33041248 PMCID: PMC8358190 DOI: 10.1016/j.bj.2020.07.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 07/17/2020] [Accepted: 07/22/2020] [Indexed: 12/19/2022] Open
Abstract
Ageing implicates a remodeling of our immune system, which is a consequence of the physiological senescence of our cells and tissues coupled with environmental factors and chronic antigen exposure. An immune system that senesces includes more differentiated cells with accumulation of highly differentiated CD4 and CD8 T cells. The pool of naive T cells decreases with the exponential thymic involution induced by age. Differentiated T cells have similar, if not higher, functional capacities but scarce studies are looking at the impact of senescence among specific T cells. After a stimulation, other immune cells (monocytes, dendritic cells and NK) are functionally altered during ageing. It is as if the immune system was more efficient at the basal level, but less efficient after a stimulation in the old compared to young people, likely due to less reserve. Concerning the clinical impact, older people are more prone to certain pathogens and their clinical manifestations differ from the younger people. Severe flu and VZV reactivation are more frequent with an altered cellular response to vaccination. Vaccination failure can have detrimental consequences in people presenting frailty criteria. Old people frailty is majored by their comorbidities and diseases like cancer. Thus, chemotherapies are employed with circumspection in older patients. The use of anti-PD-1/PD-L1 immunotherapies is therefore attractive, because of less side effects with a better response compared to chemotherapy. Old persons inclusion is lacking in current studies and clinical trials. Some subgroups or pooled analyses confirm the gain in response without increased toxicities in older patients but their inclusion criteria differ from the real-life practice. Specific studies focusing on this population are needed because of the increasing cancer incidence with age and the overall ageing of the population.
Collapse
Affiliation(s)
- C Granier
- Biological Immunology Department, APHP, Georges Pompidou European Hospital, Paris, France; University of Paris, PARCC, INSERM, APHP, Paris, France; Ligue Contre le Cancer Labeled Team, France.
| | - A Gey
- Biological Immunology Department, APHP, Georges Pompidou European Hospital, Paris, France; University of Paris, PARCC, INSERM, APHP, Paris, France; Ligue Contre le Cancer Labeled Team, France
| | - S Roncelin
- Biological Immunology Department, APHP, Georges Pompidou European Hospital, Paris, France
| | - L Weiss
- Clinical Immunology Department, APHP, Paris, France; INSERM U976 HIPI, Paris, France; Paris Descartes Medical School, University of Paris, Paris, France
| | - E Paillaud
- Department of Geriatric, APHP, Paris Cancer Institute CARPEM, Europeen Georges Pompidou Hospital, Paris, France; Paris Est Creteil University, INSERM, IMRB, Creteil, France
| | - E Tartour
- Biological Immunology Department, APHP, Georges Pompidou European Hospital, Paris, France; University of Paris, PARCC, INSERM, APHP, Paris, France; Ligue Contre le Cancer Labeled Team, France
| |
Collapse
|
5
|
Blanc C, Hans S, Tran T, Granier C, Saldman A, Anson M, Oudard S, Tartour E. Targeting Resident Memory T Cells for Cancer Immunotherapy. Front Immunol 2018; 9:1722. [PMID: 30100906 PMCID: PMC6072845 DOI: 10.3389/fimmu.2018.01722] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Accepted: 07/12/2018] [Indexed: 12/17/2022] Open
Abstract
A novel population of memory CD8+ T cells called resident memory T cells (TRM) has been identified based on their phenotype (CD103, CD69) and on their local tissue residency without recirculating in the blood. These cells have been implicated in protective immune response against pathogens in both animal models and humans. Their role in cancer is just emerging as a key player in tumor immunosurveillance. Many properties of these cells suggest that they could control tumor growth: (i) they respond much faster to reexposure to cognate antigen than circulating memory cells, (ii) they express high levels of cytotoxic molecules, and (iii) they are enriched in tumor-specific T cells in close contact with tumor cells. TRM are present in many human cancers and are associated with a good clinical outcome independently of the infiltration of CD8+ T cells. It has been recently shown that the efficacy of cancer vaccines depends on their ability to elicit TRM. In adoptive cell therapy, the transfer of cells with the ability to establish TRM at the tumor site correlates with the potency of this approach. Interestingly, TRM express immune checkpoint molecules and preliminary data showed that they could expand early during anti-PD-1 treatment, and thus be considered as a surrogate marker of response to immunotherapy. Some cues to better expand these cells in vivo and improve the success of cancer immunotherapy include using mucosal routes of immunization, targeting subpopulations of dendritic cells as well as local signal at the mucosal site to recruit them in mucosal tissue.
Collapse
Affiliation(s)
- Charlotte Blanc
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France
| | - Sophie Hans
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France
| | - Thi Tran
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France
| | - Clemence Granier
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France
| | - Antonin Saldman
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France
| | - Marie Anson
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France
| | - Stephane Oudard
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France.,Hôpital Européen Georges Pompidou, Department of Medical Oncology, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Eric Tartour
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France.,Hôpital Européen Georges Pompidou, Laboratory of Immunology, Assistance Publique des Hôpitaux de Paris, Paris, France
| |
Collapse
|
6
|
Tran T, Blanc C, Granier C, Saldmann A, Tanchot C, Tartour E. Therapeutic cancer vaccine: building the future from lessons of the past. Semin Immunopathol 2018; 41:69-85. [PMID: 29978248 DOI: 10.1007/s00281-018-0691-z] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 06/11/2018] [Indexed: 12/13/2022]
Abstract
Anti-cancer vaccines have raised many hopes from the start of immunotherapy but have not yet been clinically successful. The few positive results of anti-cancer vaccines have been observed in clinical situations of low tumor burden or preneoplastic lesions. Several new concepts and new results reposition this therapeutic approach in the field of immunotherapy. Indeed, cancers that respond to anti-PD-1/PD-L1 (20-30%) are those that are infiltrated by anti-tumor T cells with an inflammatory infiltrate. However, 70% of cancers do not appear to have an anti-tumor immune reaction in the tumor microenvironment. To induce this anti-tumor immunity, therapeutic combinations between vaccines and anti-PD-1/PD-L1 are being evaluated. In addition, the identification of neoepitopes against which the immune system is less tolerated is giving rise to a new enthusiasm by the first clinical results of the vaccine including these neoepitopes in humans. The ability of anti-cancer vaccines to induce a population of anti-tumor T cells called memory resident T cells that play an important role in immunosurveillance is also a new criterion to consider in the design of therapeutic vaccines.
Collapse
Affiliation(s)
- T Tran
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - C Blanc
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - C Granier
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - A Saldmann
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - C Tanchot
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Eric Tartour
- INSERM U970, Paris Cardiovascular Research Center (PARCC), Paris, France.
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
- Hôpital Européen Georges Pompidou, Laboratory of Immunology, Assistance Publique des Hôpitaux de Paris, Paris, France.
- Equipe Labellisée Ligue Nationale contre le Cancer, Paris, France.
| |
Collapse
|
7
|
Dall'Osto M, Beddows DCS, Asmi A, Poulain L, Hao L, Freney E, Allan JD, Canagaratna M, Crippa M, Bianchi F, de Leeuw G, Eriksson A, Swietlicki E, Hansson HC, Henzing JS, Granier C, Zemankova K, Laj P, Onasch T, Prevot A, Putaud JP, Sellegri K, Vidal M, Virtanen A, Simo R, Worsnop D, O'Dowd C, Kulmala M, Harrison RM. Novel insights on new particle formation derived from a pan-european observing system. Sci Rep 2018; 8:1482. [PMID: 29367716 PMCID: PMC5784154 DOI: 10.1038/s41598-017-17343-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Accepted: 11/20/2017] [Indexed: 11/10/2022] Open
Abstract
The formation of new atmospheric particles involves an initial step forming stable clusters less than a nanometre in size (<~1 nm), followed by growth into quasi-stable aerosol particles a few nanometres (~1–10 nm) and larger (>~10 nm). Although at times, the same species can be responsible for both processes, it is thought that more generally each step comprises differing chemical contributors. Here, we present a novel analysis of measurements from a unique multi-station ground-based observing system which reveals new insights into continental-scale patterns associated with new particle formation. Statistical cluster analysis of this unique 2-year multi-station dataset comprising size distribution and chemical composition reveals that across Europe, there are different major seasonal trends depending on geographical location, concomitant with diversity in nucleating species while it seems that the growth phase is dominated by organic aerosol formation. The diversity and seasonality of these events requires an advanced observing system to elucidate the key processes and species driving particle formation, along with detecting continental scale changes in aerosol formation into the future.
Collapse
Affiliation(s)
- M Dall'Osto
- Institute of Marine Science, Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain. .,National Centre for Atmospheric Science Division of Environmental Health & Risk Management School of Geography, Earth & Environmental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom. .,School of Physics, Centre for Climate & Air Pollution Studies, National University of Ireland Galway, University Road Galway, Galway, Ireland. .,Aerodyne Research, Inc., Billerica, MA, USA.
| | - D C S Beddows
- National Centre for Atmospheric Science Division of Environmental Health & Risk Management School of Geography, Earth & Environmental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom
| | - A Asmi
- Department of Physics, University of Helsinki, P.O. Box 64, 00014, Helsinki, Finland
| | - L Poulain
- Leibniz Institute for Tropospheric Research, Permoserstr. 15, 04318, Leipzig, Germany
| | - L Hao
- University of Eastern Finland, Department of Applied Physics, P.O.Box 1627, FIN-70211, Kuopio, Finland
| | - E Freney
- Laboratoire de Météorologie Physique, CNRS-Université Blaise Pascal, UMR6016, 63117, Clermont, Ferrand, France
| | - J D Allan
- School of Earth, Atmospheric and Environmental Sciences, The University of Manchester, Manchester, UK
| | | | - M Crippa
- Laboratory of Atmospheric Chemistry, Paul Scherrer Institute, 5232, PSI, Villigen, Switzerland.,European Commission, Joint Research Centre (JRC), Directorate for Energy, Transport and Climate, Air and Climate Unit, Via E. Fermi 2749, I-21027, Ispra, (VA), Italy
| | - F Bianchi
- Department of Physics, University of Helsinki, P.O. Box 64, 00014, Helsinki, Finland.,Laboratory of Atmospheric Chemistry, Paul Scherrer Institute, 5232, PSI, Villigen, Switzerland
| | - G de Leeuw
- Finnish Meteorological Institute, Climate Change Unit, P.O. Box 503, 00101, Helsinki, Finland.,Netherlands Organisation for Applied Scientific Research TNO, Princetonlaan 6, 3508 TA, Utrecht, The Netherlands
| | - A Eriksson
- Division of Ergonomics and Aerosol Technology, Lund University, Box 118, SE-22100, Lund, Sweden
| | - E Swietlicki
- Division of Nuclear Physics, Lund University, Box 118, SE-22100, Lund, Sweden
| | - H C Hansson
- Department of Environmental Science and Analytical Chemistry, Stockholm University, 10691, Stockholm, Sweden
| | - J S Henzing
- Netherlands Organisation for Applied Scientific Research TNO, Princetonlaan 6, 3508 TA, Utrecht, The Netherlands
| | - C Granier
- Laboratoire d'Aérologie, Toulouse, France.,NOAA Earth System Laboratory and CIRES, University of Colorado, Boulder, USA
| | - K Zemankova
- Charles University, Faculty of Mathematics and Physics, Dept. of Atmospheric Physcis, Prague, Czechia
| | - P Laj
- Department of Physics, University of Helsinki, P.O. Box 64, 00014, Helsinki, Finland.,Univ. Grenoble-Alpes, CNRS, IRD, INPG, Institut des Géosciences de l'Environnement, Grenoble, France.,Univ. Grenoble-Alpes, CNRS, IRD, Observatoire des Sciences de l'Univers, Grenoble, France
| | - T Onasch
- Aerodyne Research, Inc., Billerica, MA, USA
| | - A Prevot
- Laboratory of Atmospheric Chemistry, Paul Scherrer Institute, 5232, PSI, Villigen, Switzerland
| | - J P Putaud
- European Commission, Joint Research Centre, Institute for Environment and Sustainability, 21027, (VA), Italy
| | - K Sellegri
- Laboratoire de Météorologie Physique, CNRS-Université Blaise Pascal, UMR6016, 63117, Clermont, Ferrand, France
| | - M Vidal
- Department of Evolutionary Biology, Ecology and Environmental Sciences, Universitat de Barcelona, Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain
| | - A Virtanen
- University of Eastern Finland, Department of Applied Physics, P.O.Box 1627, FIN-70211, Kuopio, Finland
| | - R Simo
- Institute of Marine Science, Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain
| | - D Worsnop
- Aerodyne Research, Inc., Billerica, MA, USA.,Department of Physics, University of Helsinki, P.O. Box 64, 00014, Helsinki, Finland
| | - C O'Dowd
- School of Physics, Centre for Climate & Air Pollution Studies, National University of Ireland Galway, University Road Galway, Galway, Ireland
| | - M Kulmala
- Department of Physics, University of Helsinki, P.O. Box 64, 00014, Helsinki, Finland
| | - Roy M Harrison
- National Centre for Atmospheric Science Division of Environmental Health & Risk Management School of Geography, Earth & Environmental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.,Department of Environmental Sciences / Center of Excellence in Environmental Studies, King Abdulaziz University, PO Box 80203, 21589, Jeddah, Saudi Arabia
| |
Collapse
|
8
|
Mion G, Le Masson J, Granier C, Hoffmann C. A retrospective study of ketamine administration and the development of acute or post-traumatic stress disorder in 274 war-wounded soldiers. Anaesthesia 2017; 72:1476-1483. [PMID: 28972278 DOI: 10.1111/anae.14079] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/23/2017] [Indexed: 12/23/2022]
Abstract
The objective of this study was to explore whether ketamine prevents or exacerbates acute or post-traumatic stress disorders in military trauma patients. We conducted a retrospective study of a database from the French Military Health Service, including all soldiers surviving a war injury in Afghanistan (2010-2012). The diagnosis of post-traumatic stress disorder was made by a psychiatrist and patients were analysed according to the presence or absence of this condition. Analysis included the following covariables: age; sex; acute stress disorder; blast injury; associated fatality; brain injury; traumatic amputation; Glasgow coma scale; injury severity score; administered drugs; number of surgical procedures; physical, neurosensory or aesthetic sequelae; and the development chronic pain. Covariables related to post-traumatic and acute stress disorders with a p ≤ 0.10 were included in a multivariable logistic regression model. The data from 450 soldiers were identified; 399 survived, of which 274 were analysed. Among these, 98 (36%) suffered from post-traumatic stress disorder and 89 (32%) had received ketamine. Fifty-four patients (55%) in the post-traumatic stress disorder group received ketamine vs. 35 (20%) in the no PTSD group (p < 0.001). The 89 injured soldiers who received ketamine had a median (IQR [range]) injury severity score of 5 (3-13 [1-26]) vs. 3 (2-4 [1-6] in the 185 patients who did not (p < 0.001). At multivariable analysis, only acute stress disorder and total number of surgical procedures were independently associated with the development of post-traumatic stress disorder. In this retrospective study, ketamine administration was not a risk factor for the development of post-traumatic stress disorder in the military trauma setting.
Collapse
Affiliation(s)
- G Mion
- Anaesthesia Department, Cochin Hospital, Paris, France
| | | | - C Granier
- Psychiatry Department, Paul Guiraud Hospital, Villejuif, France
| | - C Hoffmann
- Burn Center, Percy Military Teaching Hospital, Clamart, France
| |
Collapse
|
9
|
Granier C, Blanc C, Karaki S, Tran T, Roussel H, Tartour E. Tissue-resident memory T cells play a key role in the efficacy of cancer vaccines. Oncoimmunology 2017; 6:e1358841. [PMID: 29147623 DOI: 10.1080/2162402x.2017.1358841] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Accepted: 07/19/2017] [Indexed: 10/19/2022] Open
Abstract
Resident memory CD8+T cells (TRM) usually defined by the CD103 marker represent a new subset of long-lived memory T cells that remain in the tissues. We directly demonstrate their specific role in cancer vaccine-induced tumor regression. In human, they also seem to play a major role in tumor immunosurveillance.
Collapse
Affiliation(s)
- C Granier
- INSERMU970, Université Paris Descartes Sorbonne Paris-Cité, 56 Rue Leblanc Paris, France
| | - C Blanc
- INSERMU970, Université Paris Descartes Sorbonne Paris-Cité, 56 Rue Leblanc Paris, France
| | - S Karaki
- INSERMU970, Université Paris Descartes Sorbonne Paris-Cité, 56 Rue Leblanc Paris, France
| | - T Tran
- INSERMU970, Université Paris Descartes Sorbonne Paris-Cité, 56 Rue Leblanc Paris, France
| | - H Roussel
- INSERMU970, Université Paris Descartes Sorbonne Paris-Cité, 56 Rue Leblanc Paris, France
| | - E Tartour
- INSERMU970, Université Paris Descartes Sorbonne Paris-Cité, 56 Rue Leblanc Paris, France.,Hopital Européen Georges Pompidou, Department of Immunology, 20 Rue Leblanc Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| |
Collapse
|
10
|
Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open 2017; 2:e000213. [PMID: 28761757 PMCID: PMC5518304 DOI: 10.1136/esmoopen-2017-000213] [Citation(s) in RCA: 204] [Impact Index Per Article: 29.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 05/05/2017] [Indexed: 12/25/2022] Open
Abstract
The large family of costimulatory molecules plays a crucial role in regulation of the immune response. These molecules modulate TCR signalling via phosphorylation cascades. Some of the coinhibitory members of this family, such as PD-1 and CTLA-4, already constitute approved targets in cancer therapy and, since 2011, have opened a new area of antitumour immunotherapy. Many antibodies targeting other inhibitory receptors (Tim-3, VISTA, Lag-3 and so on) or activating costimulatory molecules (OX40, GITR and so on) are under evaluation. These antibodies have multiple mechanisms of action. At the cellular level, these antibodies restore the activation signalling pathway and reprogram T cell metabolism. Tumour cells become resistant to apoptosis when an intracellular PD-L1 signalling is blocked. CD8+ T cells are considered to be the main effectors of the blockade of inhibitory receptors. Certain CD8+ T cell subsets, such as non-hyperexhausted (CD28+, T-bethigh, PD-1int), follicular-like (CXCR-5+) or resident memory CD8+ T cells, are more prone to be reactivated by anti-PD-1/PD-L1 monoclonal antibody (mAb). In the future, the challenge will be to rationally combine drugs able to make the tumour microenvironment more permissive to immunotherapy in order to potentiate its clinical activity.
Collapse
Affiliation(s)
- Clemence Granier
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Eleonore De Guillebon
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Department of medical oncology, Hopital Européen Georges Pompidou, Paris, France
| | - Charlotte Blanc
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Helene Roussel
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Department of Pathology, Hôpital Européen Georges Pompidou, Paris, France
| | - Cecile Badoual
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Department of Pathology, Hôpital Européen Georges Pompidou, Paris, France
| | - Elia Colin
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Antonin Saldmann
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Department of Immunology, Hôpital Européen Georges Pompidou, Paris, France
| | - Alain Gey
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Department of Immunology, Hôpital Européen Georges Pompidou, Paris, France
| | - Stephane Oudard
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Department of medical oncology, Hopital Européen Georges Pompidou, Paris, France
| | - Eric Tartour
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France.,Department of Immunology, Hôpital Européen Georges Pompidou, Paris, France
| |
Collapse
|
11
|
Asso M, Granier C, Rietschoten JV, Benlian D. Etude des complexes de zinc et de praseodyme avec l’aspartylalanylhistidine amide par potentiometrie et resonance magnetique nucléaire. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1982790455] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
12
|
Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, Marcheteau E, Fabre E, Mandavit M, Terme M, Blanc C, Escudie JB, Gibault L, Barthes FLP, Granier C, Ferreira LCS, Badoual C, Johannes L, Tartour E. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun 2017; 8:15221. [PMID: 28537262 PMCID: PMC5458068 DOI: 10.1038/ncomms15221] [Citation(s) in RCA: 197] [Impact Index Per Article: 28.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2016] [Accepted: 03/10/2017] [Indexed: 12/20/2022] Open
Abstract
Tissue-resident memory T cells (Trm) represent a new subset of long-lived memory T cells that remain in tissue and do not recirculate. Although they are considered as early immune effectors in infectious diseases, their role in cancer immunosurveillance remains unknown. In a preclinical model of head and neck cancer, we show that intranasal vaccination with a mucosal vector, the B subunit of Shiga toxin, induces local Trm and inhibits tumour growth. As Trm do not recirculate, we demonstrate their crucial role in the efficacy of cancer vaccine with parabiosis experiments. Blockade of TFGβ decreases the induction of Trm after mucosal vaccine immunization, resulting in the lower efficacy of cancer vaccine. In order to extrapolate this role of Trm in humans, we show that the number of Trm correlates with a better overall survival in lung cancer in multivariate analysis. The induction of Trm may represent a new surrogate biomarker for the efficacy of cancer vaccine. This study also argues for the development of vaccine strategies designed to elicit them.
Collapse
Affiliation(s)
- Mevyn Nizard
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Hélène Roussel
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France.,Department of Pathology, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France
| | - Mariana O Diniz
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Institute of Biomedical Sciences, University of Sao Paulo, Av Prof Lineu Prestes, Sao Paulo SP-CEP 05508-900, Brazil
| | - Soumaya Karaki
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Thi Tran
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Thibault Voron
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Estelle Dransart
- Institut Curie, PSL Research University, Chemical Biology of Membranes and Therapeutic Delivery Unit, INSERM U 1143, CNRS UMR3666, 26 Rue d'Ulm 75248, Paris Cedex 05, France
| | - Federico Sandoval
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Marc Riquet
- Hopital Europeen Georges Pompidou, Chrirurgie Thoracique Générale, Oncologique et Transplantation, 20 Rue Leblanc, Paris 75015, France
| | - Bastien Rance
- Department of Medical Bioinformatics, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France
| | - Elie Marcheteau
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Elizabeth Fabre
- Departement of Medical Oncology, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France
| | - Marion Mandavit
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Magali Terme
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Charlotte Blanc
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Jean-Baptiste Escudie
- Department of Medical Bioinformatics, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France
| | - Laure Gibault
- Department of Pathology, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France
| | - Françoise Le Pimpec Barthes
- Hopital Europeen Georges Pompidou, Chrirurgie Thoracique Générale, Oncologique et Transplantation, 20 Rue Leblanc, Paris 75015, France
| | - Clemence Granier
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France
| | - Luis C S Ferreira
- Institute of Biomedical Sciences, University of Sao Paulo, Av Prof Lineu Prestes, Sao Paulo SP-CEP 05508-900, Brazil
| | - Cecile Badoual
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France.,Department of Pathology, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France
| | - Ludger Johannes
- Institut Curie, PSL Research University, Chemical Biology of Membranes and Therapeutic Delivery Unit, INSERM U 1143, CNRS UMR3666, 26 Rue d'Ulm 75248, Paris Cedex 05, France
| | - Eric Tartour
- INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France.,Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France.,Department of Pathology, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France
| |
Collapse
|
13
|
Malissen N, Macagno N, Granjeaud S, Granier C, Moutardier V, Gaudy Marqueste C, Habel N, Mandavit M, Guillot B, Pasero C, Tartour E, Ballotti R, Grob JJ, Olive D. HVEM: A novel cosignaling molecule of major interest in melanoma. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e14591] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14591 Background: Herpes Virus Entry Mediator (HVEM) is a member of the TNF superfamily, its ligation of the immunoglobulin family member B-lymphocyte and T-lymphocyte attenuator (BTLA) activates inhibitory signaling in T-cells and could play a role in evading host anti-tumor immunity. Ectopic overexpression of HVEM is associated with poor survival in some solid tumors. Our objectives were: -to evaluate HVEM expression in melanoma (MM) -to explore potential link of its overexpression with clinical outcomes -to understand the mechanisms by which HVEM was ectopically expressed in MM, and how HVEM-BTLA may play a role in MM. Methods: HVEM expression was analyzed by IHC in formalin-fixed samples of mm metastases and was correlated with OS in 130 patients. To better understand how HVEM could interfere with prognosis, relation of HVEM with its ligand BTLA was studied in the tumor and tumor microenvironment on 15 fresh metastases by flow cytometry after tumor dissociation. Bioinformatic studies based on TCGA and CCLE data combined to targeting of candidate genes by siRNA were used to investigate HVEM regulation on MM. Results: Patients with high HVEM expression on mm cells in their metastases have a significantly (p = 0.0142) poorer overall survival than those with a low expression. TCGA transcriptomic data support these results. From the mechanistic point of view, we could show that 1-HVEM expressed at the tumor cell surface interacts with BTLA expressed by tumor-infiltrated lymphocytes. 2-HVEM expression is neither linked to the mm mutational status nor inducible by IFN 3-Genes co-regulated with HVEM are associated with an aggressive gene signature 4- HVEM strongly correlate with MITF expression, MITF binds HVEM promoter, and its downregulation by siRNA results in a decrease in HVEM expression. Conclusions: A high expression of HVEM by mm metastases seems to be a pejorative prognostic marker. HVEM-BTLA interaction is a co-signaling system similar to the PD1-PDL1 one, but seem to be constitutive rather than inducible. HVEM and its co-regulated genes may constitute a signature of aggressiveness associated to MITF. High HVEM expression on mm cells may dampen anti-tumor immune responses, making HVEM and BTLA potential new targets for “checkpoint blockade” therapy.
Collapse
Affiliation(s)
| | | | | | | | | | - Caroline Gaudy Marqueste
- Dermatology and Skin Cancers Department, UMR911 CRO2 Timone Hospital, Aix-Marseille University, Marseille, France
| | - Nadia Habel
- Université Nice Côte d’Azur, Inserm U1065, C3M, Team 1, Biology and pathologies of melanocytes, Nice, France
| | | | | | | | - Eric Tartour
- Unité d'Immunologie Biologique, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France
| | - Robert Ballotti
- Université Nice Côte d’Azur, Inserm U1065, C3M, Team 1, Biology and pathologies of melanocytes, Nice, France
| | - Jean Jacques Grob
- Aix-Marseille University and APHM Hospital CHU Timone, Marseille, France
| | - Daniel Olive
- Institut Paoli-Calmettes CRCM U1068, Marseille, France
| |
Collapse
|
14
|
Granier C, Karaki S, Roussel H, Badoual C, Tran T, Anson M, Fabre E, Oudard S, Tartour E. Immunothérapie des cancers : rationnel et avancées récentes. Rev Med Interne 2016; 37:694-700. [DOI: 10.1016/j.revmed.2016.05.023] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2016] [Accepted: 05/28/2016] [Indexed: 12/24/2022]
|
15
|
Koteff J, Lake J, Currier J, Brennan C, Gartland M, Shaefer M, Wynne B, Granier C, Aboud M. VIH-16 - Biomarqueurs cardiovasculaires après switch vers DTG/ABC/3TC dans l’essai striiving. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30561-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Koteff J, Trottier B, Lake J, Logue K, Brinson C, Santiago L, Brennan C, Wynne B, Granier C, Aboud M. VIH-17 - Le switch d’une trithérapie de 2 inti associés à un IP, un INNTI ou un INI par DTG/ABC/3TC maintient la suppression virologique à 24 semaines. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30562-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Demarest J, Quercia R, Zolopa A, Clair MS, Wynne B, Underwood M, Granier C, Aboud M. VIH-24 - Analyse intégrée de l’émergence d’une résistance aux antirétroviraux sur 96 et 144 semaines issue des études cliniques chez des sujets naïfs de traitement contre le VIH-1 et recevant des traitements à base de dolutégravir. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30569-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Maurin C, Delolme MP, Granier C, Kodjikian L, Chiambaretta F. [A form of macular serpiginous choroiditis]. J Fr Ophtalmol 2016; 39:e85-8. [PMID: 26951876 DOI: 10.1016/j.jfo.2015.01.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 01/15/2015] [Accepted: 01/22/2015] [Indexed: 10/22/2022]
Affiliation(s)
- C Maurin
- Service d'ophtalmologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
| | - M-P Delolme
- Service d'ophtalmologie, centre hospitalier Émile-Roux, 12, boulevard Docteur-André-Chantemesse, 43000 Le-Puy-en-Velay, France
| | - C Granier
- Service d'ophtalmologie, centre hospitalier Émile-Roux, 12, boulevard Docteur-André-Chantemesse, 43000 Le-Puy-en-Velay, France
| | - L Kodjikian
- Service d'ophtalmologie, hôpital de la Croix-Rousse, groupement hospitalier Nord, hospices civils de Lyon, 103, Grande rue de la Croix-Rousse, 69317 Lyon cedex 04, France
| | - F Chiambaretta
- Service d'ophtalmologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| |
Collapse
|
19
|
Schneider FS, de Almeida Lima S, Reis de Ávila G, Castro KL, Guerra-Duarte C, Sanchez EF, Nguyen C, Granier C, Molina F, Chávez-Olortegui C. Identification of protective B-cell epitopes of Atroxlysin-I: A metalloproteinase from Bothrops atrox snake venom. Vaccine 2016; 34:1680-7. [PMID: 26917009 DOI: 10.1016/j.vaccine.2016.02.035] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Revised: 02/11/2016] [Accepted: 02/12/2016] [Indexed: 12/30/2022]
Abstract
Atroxlysin-I (Atr-I) is a hemorrhagic snake venom metalloproteinase (SVMP) from Bothrops atrox venom, the snake responsible for the majority of bites in the north region of South America. SVMPs like Atr-I produce toxic effects in victims including hemorrhage, inflammation, necrosis and blood coagulation deficiency. Mapping of B-cell epitopes in SVMPs might result in the identification of non-toxic molecules capable of inducing neutralizing antibodies and improving the anti-venom therapy. Here, using the SPOT-synthesis technique we identified two epitopes located in the N-ter region of Atr-I (AtrEp1-(22)YNGNSDKIRRRIHQM(36); and AtrEp2-(55)GVEIWSNKDLINVQ(68)). Based on the sequence of AtrEp1 and AtrEp2 a third peptide named Atr-I biepitope (AtrBiEp) was designed and synthesized ((23)NGNSDKIRRRIH(34)GG(55)GVEIWSNKDLINVQ(68)). AtrBiEp was used to immunize BALB/c mice. Anti-AtrBiEp serum cross-reacted against Atr-I in western blot and was able to fully neutralize the hemorrhagic activity of Atr-I. Our results provide a rational basis for the identification of neutralizing epitopes on Atr-I snake venom toxin and show that the use of synthetic peptides could improve the generation of immuno-therapeutics.
Collapse
Affiliation(s)
- F S Schneider
- Departamento de Bioquímica e Imunologia, Instituto Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Sys2Diag, FRE 3690, CNRS Alcediag, Languedoc-Roussillon, Montpellier, France
| | - S de Almeida Lima
- Departamento de Bioquímica e Imunologia, Instituto Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - G Reis de Ávila
- Departamento de Bioquímica e Imunologia, Instituto Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - K L Castro
- Departamento de Bioquímica e Imunologia, Instituto Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - C Guerra-Duarte
- Departamento de Bioquímica e Imunologia, Instituto Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - E F Sanchez
- Diretoria de Pesquisa e Desenvolvimento, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil
| | - C Nguyen
- Sys2Diag, FRE 3690, CNRS Alcediag, Languedoc-Roussillon, Montpellier, France
| | - C Granier
- Sys2Diag, FRE 3690, CNRS Alcediag, Languedoc-Roussillon, Montpellier, France
| | - F Molina
- Sys2Diag, FRE 3690, CNRS Alcediag, Languedoc-Roussillon, Montpellier, France
| | - C Chávez-Olortegui
- Departamento de Bioquímica e Imunologia, Instituto Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
| |
Collapse
|
20
|
Lapalud P, Rothschild C, Mathieu-Dupas E, Balicchi J, Gruel Y, Laune D, Molina F, Schved JF, Granier C, Lavigne-Lissalde G. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A. J Thromb Haemost 2015; 13:540-7. [PMID: 25603934 DOI: 10.1111/jth.12846] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Accepted: 12/03/2014] [Indexed: 11/30/2022]
Abstract
BACKGROUND Hemophilia A (HA) is a congenital bleeding disorder resulting from factor VIII deficiency. The most serious complication of HA management is the appearance of inhibitory antibodies (Abs) against injected FVIII concentrates. To eradicate inhibitors, immune tolerance induction (ITI) is usually attempted, but it fails in up to 30% of cases. Currently, no undisputed predictive marker of ITI outcome is available to facilitate the clinical decision. OBJECTIVES To identify predictive markers of ITI efficacy. METHODS The isotypic and epitopic repertoires of inhibitory Abs were analyzed in plasma samples collected before ITI initiation from 15 children with severe HA and high-titer inhibitors, and their levels were compared in the two outcome groups (ITI success [n = 7] and ITI failure [n = 8]). The predictive value of these candidate biomarkers and of the currently used indicators (inhibitor titer and age at ITI initiation, highest inhibitor titer before ITI, and interval between inhibitor diagnosis and ITI initiation) was then compared by statistical analysis (Wilcoxon test and receiver receiver operating characteristic [ROC] curve analysis). RESULTS Whereas current indicators seemed to fail in discriminating patients in the two outcome groups (ITI success or failure), anti-A1 and anti-A2 Ab levels before ITI initiation appeared to be good potential predictive markers of ITI outcome (P < 0.018). ROC analysis showed that anti-A1 and anti-A2 Abs were the best at discriminating between outcome groups (area under the ROC curve of > 0.875). CONCLUSION Anti-A1 and anti-A2 Abs could represent new promising tools for the development of ITI outcome prediction tests for children with severe HA.
Collapse
Affiliation(s)
- P Lapalud
- UMR3145 CNRS/BioRad, SysDiag, Montpellier, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Carosi G, Lazzarin A, Stellbrink H, Moyle G, Rugina S, Staszewski S, Givens N, Ross L, Granier C, Ait-Khaled M, Leather D, Nichols WG. Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects. HIV Clinical Trials 2015; 10:356-67. [DOI: 10.1310/hct1006-356] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
22
|
Lebreton A, Simon N, Moreau V, Demolombe V, Cayzac C, Nguyen C, Schved JF, Granier C, Lavigne-Lissalde G. Computer-predicted peptides that mimic discontinuous epitopes on the A2 domain of factor VIII. Haemophilia 2014; 21:e193-e201. [PMID: 25422151 DOI: 10.1111/hae.12575] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/28/2014] [Indexed: 12/21/2022]
Abstract
Development of antibodies (Abs) against factor VIII (FVIII) is a severe complication of haemophilia A treatment. Recent publications suggest that domain specificity of anti-FVIII antibodies, particularly during immune tolerance induction (ITI), might be related to the outcome of the treatment. Obtaining suitable tools for a fine mapping of discontinuous epitopes could thus be helpful. The aim of this study was to map discontinuous epitopes on FVIII A2 domain using a new epitope prediction functionality of the PEPOP bioinformatics tool and a peptide inhibition assay based on the Luminex technology. We predicted, selected and synthesized 40 peptides mimicking discontinuous epitopes on the A2 domain of FVIII. A new inhibition assays using Luminex technology was performed to identify peptides able to inhibit the binding of anti-A2 Abs to A2 domain. We identified two peptides (IFKKLYHVWTKEVG and LYSRRLPKGVKHFD) able to block the binding of anti-A2 allo-antibodies to this domain. The three-dimensional representation of these two peptides on the A2 domain revealed that they are localized on a limited region of A2. We also confirmed that residues 484-508 of the A2 domain define an antigenic site. We suggest that dissection of the antibody response during ITI using synthetic peptide epitopes could provide important information for the management of patients with inhibitors.
Collapse
Affiliation(s)
- A Lebreton
- UMR 3145 SysDiag CNRS/Bio-Rad, Parc Euromédecine, Montpellier, France; CHU Clermont-Ferrand, Service d'Hématologie Biologique, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Zitvogel L, Tanchot C, Granier C, Tartour E. Following up tumor-specific regulatory T cells in cancer patients. Oncoimmunology 2014; 2:e25444. [PMID: 24073383 PMCID: PMC3782156 DOI: 10.4161/onci.25444] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2013] [Accepted: 06/18/2013] [Indexed: 01/13/2023] Open
Affiliation(s)
- Laurence Zitvogel
- INSERM, U1015; Villejuif, France ; Institut Gustave Roussy; Villejuif, France ; CICBT507; Villejuif, France ; Université Paris Sud; Le Kremlin Bicêtre, France
| | | | | | | |
Collapse
|
24
|
Yazdanpanah Y, Khuong-Josses MA, Hocqueloux L, Pialoux G, Durant J, Wynne B, Granier C, Tebas P, Pappa K, Min S. 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial. BMC Infect Dis 2014. [PMCID: PMC4221003 DOI: 10.1186/1471-2334-14-s2-p72] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
25
|
Dias-Lopes C, Felicori L, Rubrecht L, Cobo S, Molina L, Nguyen C, Galéa P, Granier C, Molina F, Chávez-Olortegui C. Generation and molecular characterization of a monoclonal antibody reactive with conserved epitope in sphingomyelinases D from Loxosceles spider venoms. Vaccine 2014; 32:2086-92. [DOI: 10.1016/j.vaccine.2014.02.012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Revised: 01/21/2014] [Accepted: 02/06/2014] [Indexed: 02/05/2023]
|
26
|
Nizard M, Sandoval F, Badoual C, Pere H, Terme M, Hans S, Benhamouda N, Granier C, Brasnu D, Tartour E. Immunotherapy of HPV-associated head and neck cancer: Critical parameters. Oncoimmunology 2013; 2:e24534. [PMID: 23894716 PMCID: PMC3716751 DOI: 10.4161/onci.24534] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2013] [Accepted: 04/03/2013] [Indexed: 11/19/2022] Open
Abstract
Various arguments support the development of a vaccine targeting human papillomavirus (HPV) for the treatment of HPV-associated head and neck cancer. However, the mucosal localization of this tumor, the HPV-driven downregulation of MHC Class I molecules and various other immunosuppressive mechanisms must be carefully considered to improve the clinical efficacy of such an immunotherapeutic strategy.
Collapse
Affiliation(s)
- Mevyn Nizard
- INSERM U970 PARCC; Université Paris Descartes; Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Lapalud P, Ali T, Cayzac C, Mathieu-Dupas E, Levesque H, Pfeiffer C, Balicchi J, Gruel Y, Borg JY, Schved JF, Granier C, Lavigne-Lissalde G. The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII. J Thromb Haemost 2012; 10:1814-22. [PMID: 22784315 DOI: 10.1111/j.1538-7836.2012.04850.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Acquired hemophilia A (AHA) is a severe life-threatening autoimmune disease due to the development of autoantibodies that neutralize the procoagulant activity of factor VIII (FVIII). In rare cases, AHA occurs in the postpartum period as a serious complication of an otherwise normal pregnancy and delivery. Due to its rarity, little is known about the features of the antibody response to FVIII in AHA. OBJECTIVES Our study wanted to (i) determine the epitope specificity and the immunoglobulin (Ig) subclasses of anti-FVIII autoantibodies in plasma samples from a large cohort of AHA patients, and (ii) compare the epitope specificity of anti-FVIII autoantibodies in plasma samples from postpartum AHA and other AHA patients. PATIENTS/METHODS Seventy-three plasma samples from patients with postpartum AHA (n = 10) or associated with malignancies (n = 16) or autoimmune diseases (n = 11) or without underlying disease (n = 36) were analyzed with three multiplexed assays. RESULTS AND CONCLUSIONS Our results showed a stronger response against the A1a1-A2a2-B fragments of FVIII and more specifically against the A1a1 domain in patients with postpartum AHA than in the other AHA groups (P < 0.01). Moreover, although IgG4 was the predominant IgG subclass in all groups, anti-A1a1-A2a2-B and anti-A1a1 domain autoantibodies of the IgG(1) and IgG3 subclasses were more frequently detected in postpartum AHA than in the other AHA groups. These findings support the involvement of the Th1-driven response in the generation of autoantibodies in women with postpartum AHA compared with the other groups of AHA patients in whom production of Th2-driven IgG4 was predominant.
Collapse
Affiliation(s)
- P Lapalud
- SysDiag, UMR3145 CNRS/BioRad, Montpellier, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Pugnet G, Astudillo L, Bouchet J, Granier C, Bagheri H, Montastruc JL, Sailler L, Arlet P. La gynécomastie douloureuse : un effet indésirable rare du méthotrexate chez un patient atteint de polyarthrite rhumatoïde. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.03.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Machado de Avila RA, Stransky S, Velloso M, Castanheira P, Schneider FS, Kalapothakis E, Sanchez EF, Nguyen C, Molina F, Granier C, Chávez-Olórtegui C. Mimotopes of mutalysin-II from Lachesis muta snake venom induce hemorrhage inhibitory antibodies upon vaccination of rabbits. Peptides 2011; 32:1640-6. [PMID: 21763377 DOI: 10.1016/j.peptides.2011.06.028] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2011] [Revised: 06/29/2011] [Accepted: 06/29/2011] [Indexed: 11/24/2022]
Abstract
Mutalysin-II (mut-II) from Lachesis muta snake venom is an endopeptidase with hemorrhagic activity. A mAb against mutalysin-II that neutralized the hemorrhagic effect was produced previously. To identify the mAb epitopes, sets of 15-mer overlapping peptides covering the mut-II amino acid sequence were synthesized using the SPOT method and tested but failed to react with the mAb. Using a phage-display approach seventeen clones reactive with mAb were identified. Additional immunoassays with the peptides and mAb identified the QCTMDQGRLRCR, TCATDQGRLRCT, HCFHDQGRVRCA, HCTMDQGRLRCR and SCMLDQGRSRCR sequences as possible epitopes. Immunization of rabbits with these peptides induced antibodies that recognize mut-II and protected against the hemorrhagic effects of Lachesis venom.
Collapse
Affiliation(s)
- R A Machado de Avila
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, CEP 31270-901, Belo Horizonte-MG, Brazil
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Dias-Lopes C, Guimarães G, Felicori L, Fernandes P, Emery L, Kalapothakis E, Nguyen C, Molina F, Granier C, Chávez-Olórtegui C. A protective immune response against lethal, dermonecrotic and hemorrhagic effects of Loxosceles intermedia venom elicited by a 27-residue peptide. Toxicon 2010; 55:481-7. [DOI: 10.1016/j.toxicon.2009.09.019] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2009] [Revised: 09/18/2009] [Accepted: 09/29/2009] [Indexed: 11/29/2022]
|
31
|
Alvarenga L, Moreau V, Felicori L, Nguyen C, Duarte C, Chavez-Olortegui C, Molina F, Martin-Eauclaire MF, Granier C. Design of antibody-reactive peptides from discontinuous parts of scorpion toxins. Vaccine 2010; 28:970-80. [DOI: 10.1016/j.vaccine.2009.10.135] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2009] [Revised: 10/27/2009] [Accepted: 10/28/2009] [Indexed: 10/20/2022]
|
32
|
Kim SW, Heckel A, Frost GJ, Richter A, Gleason J, Burrows JP, McKeen S, Hsie EY, Granier C, Trainer M. NO2columns in the western United States observed from space and simulated by a regional chemistry model and their implications for NOxemissions. ACTA ACUST UNITED AC 2009. [DOI: 10.1029/2008jd011343] [Citation(s) in RCA: 130] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
33
|
Hell RCR, Amim P, de Andrade HM, de Avila RAM, Felicori L, Oliveira AG, Oliveira CA, Nascimento E, Tavares CAP, Granier C, Chávez-Olórtegui C. Immunodiagnosis of human neurocysticercosis using a synthetic peptide selected by phage-display. Clin Immunol 2009; 131:129-38. [PMID: 19186111 DOI: 10.1016/j.clim.2008.10.012] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2008] [Revised: 09/23/2008] [Accepted: 10/27/2008] [Indexed: 11/28/2022]
Abstract
The usefulness of a synthetic peptide in the serodiagnosis of Taenia solium human neurocysticercosis (NC) has been evaluated. Phage-displayed peptides were screened with human antibodies to scolex protein antigen from cysticercus cellulosae (SPACc). One clone was found to interact specifically with anti-SPACc IgGs. The corresponding synthetic peptide was found to be recognized in ELISA by NC patient's sera. The study was carried out with sera from 28 confirmed NC patients, 13 control sera and 73 sera from patients suffering from other infectious diseases. A 93% sensibility and a 94.3% specificity was achieved. Figures of 89% and 31.4% of sensibility and specificity were obtained in a SPACc-based ELISA. Immunoblotting of SPACc with anti-peptide antibodies revealed a single band of approximately 45 kDa in 1D and four 45 kDa isoforms in 2D-gel electrophoresis. A strong and specific immunostaining in the fibers beneath the suckers, at the base of the rostellum, and in the tissue surrounding the scolex of cysticerci was observed by immunomicroscopy. Our results show that a peptide-based immunodiagnostic of neurocisticercosis can be envisioned.
Collapse
Affiliation(s)
- R C R Hell
- Departamento de Bioquímica-Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte-MG, Brazil
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Makni K, Jarraya F, Rebaï M, Mnif F, Boudawara M, Hamza N, Rekik N, Abid M, Hachicha J, Granier C, Rebaï A, Ayadi H. Risk genotypes and haplotypes of the GLUT1 gene for type 2 diabetic nephropathy in the Tunisian population. Ann Hum Biol 2008; 35:490-8. [PMID: 18821326 DOI: 10.1080/03014460802247142] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVE Diabetic nephropathy (DN) is a long-term complication of both type 1 and type 2 diabetes. Genetic studies on DN have been of little help so far, since several genetic association studies have shown conflicting results. Here we report the findings of a case-control study on five SNPs in the glucose transporter 1 (GLUT1) gene. The study investigated the association of five GLUT1 genotypes and haplotypes with DN. RESEARCH DESIGN AND METHODS All subjects, 126 DN (cases) and 273 type 2 diabetes (controls), were genotyped using the polymerase chain reaction restriction fragment length polymorphism. RESULTS The TT and the AA genotypes of the Haell and Enh2 SNP1, increased the risk of DN. The study also identified CGT as the highest risk haplotype (4.4-fold) followed by CAT with an increased risk of DN of 2.6-fold. CONCLUSIONS The GLUT1 gene confers susceptibility to DN in type 2 diabetes patients in the Tunisian population.
Collapse
Affiliation(s)
- K Makni
- Research Unit Target for Diagnosis and Therapeutic in the Human Pathology, Center of Biotechnology of Sfax, Tunisia.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Makni K, Mnif F, Boudawara M, Hamza N, Rekik N, Abid M, Rebaï A, Jarraya F, Granier C, Ayadi H. Association of glucose transporter 1 polymorphisms with type 2 diabetes in the Tunisian population. Diabetes Metab Res Rev 2008; 24:544-8. [PMID: 18613291 DOI: 10.1002/dmrr.866] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND T2DM is a complex metabolic disease. Genetic studies on T2DM have been of little help so far because several genetic association studies have shown conflicting results. In this study, we report the findings of a case-control study on three SNPs in the GLUT1 gene. For this, we investigated the association of GLUT1 genotypes and haplotypes with T2DM. RESEARCH DESIGN AND METHODS All 273 T2DM subjects (cases) and 343 healthy subjects (controls) were genotyped using the polymerase chain reaction restriction fragment length polymorphism. RESULTS Results showed that the GT genotype of XbaI SNP could increase the risk of susceptibility to T2DM to 2.4 and that TAT is a 'risk haplotype' conferring a risk of 3.4 to T2DM. CONCLUSION The TAT haplotype of the GLUT1 gene confers susceptibility to T2DM in the Tunisian population.
Collapse
Affiliation(s)
- K Makni
- Research Unit 'Targets for Diagnostic and Therapy of Human Diseases', Centre of Biotechnology of Sfax, and Laboratoire International Associé No 135, Sfax, Tunisia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Chaves DG, Velloso-Rodrigues C, Moreau V, Nguyen C, Villard S, Belisário AR, Granier C, Santoro MM. Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains. Br J Haematol 2008; 141:708-15. [PMID: 18422780 DOI: 10.1111/j.1365-2141.2008.07043.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Antibodies (Abs) that block factor VIII (FVIII) activity occur in hemophilia A patients treated with FVIII replacement therapy and severely impair treatment. In this work, we designed and synthesized ten peptides whose sequences are found in putative epitopes at the surface of a1 and C2 domains of the FVIII molecule. These peptides were screened for their ability to inhibit the binding of anti-FVIII Abs from plasmas of hemophilia A patients to FVIII. All peptides were efficient in inhibiting anti-FVIII Abs in plasma from patients with inhibitors, with however different efficiencies. It was found that each tested patient's plasma had a different profile of reactivity with peptides, consistent with an individual anti-FVIII Ab specificity. The profile of recognized peptides was also changing during the treatment of the patients. Three peptides were used in an affinity chromatography assay to attempt to remove anti-FVIII Abs from patients' plasma. Anti-FVIII IgGs were significantly captured by the peptide-Sepharose affinity matrixes as assessed by enzyme-linked immunosorbent assay. However, due to the low level of Abs in the plasma samples, other methods (Chromogenic and Bethesda assays) were not sensitive enough to properly detect the reduction of inhibitors.
Collapse
Affiliation(s)
- D G Chaves
- Department of Biochemistry and Immunology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Rubio R, Johnson MA, Haas BJ, Loeschel EA, Granier C, Jackson F, Pearce HC. Safety personalisation of ART therapy: what treatments do patients receive with the knowledge of their HLA-B*5701 status? J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
38
|
Kalapothakis E, Chatzaki M, Gonçalves-Dornelas H, de Castro CS, Silvestre FG, Laborne FV, de Moura JF, Veiga SS, Chávez-Olórtegui C, Granier C, Barbaro KC. The Loxtox protein family in Loxosceles intermedia (Mello-Leitão) venom. Toxicon 2007; 50:938-46. [PMID: 17825864 DOI: 10.1016/j.toxicon.2007.07.001] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2007] [Revised: 07/02/2007] [Accepted: 07/03/2007] [Indexed: 11/23/2022]
Abstract
We isolated cDNA sequences coding for dermonecrotic/sphingomyelinases factor proteins from the brown spider Loxosceles intermedia, here named Loxtox proteins. The amino acid sequences based on cloned cDNA of several Loxtox proteins revealed at least six distinct groups of proteins expressed in the venom gland. The level of similarity among the toxins varied from 99% to 55%. The finding of several isoforms of Loxtox in the venom of this spider may reflect an evolutionary adaptation for different prey types and reinforces the idea of an efficient mutational mechanism in the venom gland of spiders.
Collapse
Affiliation(s)
- E Kalapothakis
- Departamento de Biologia Geral Instituto de Ciências Biológicas; Universidade Federal de Minas Gerais, CEP 31270901 Belo Horizonte, MG, Brazil.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Kinnison DE, Brasseur GP, Walters S, Garcia RR, Marsh DR, Sassi F, Harvey VL, Randall CE, Emmons L, Lamarque JF, Hess P, Orlando JJ, Tie XX, Randel W, Pan LL, Gettelman A, Granier C, Diehl T, Niemeier U, Simmons AJ. Sensitivity of chemical tracers to meteorological parameters in the MOZART-3 chemical transport model. ACTA ACUST UNITED AC 2007. [DOI: 10.1029/2006jd007879] [Citation(s) in RCA: 351] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
40
|
Granier C, Makni K, Molina L, Jardin-Watelet B, Ayadi H, Jarraya F. Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant 2007; 23:792-9. [DOI: 10.1093/ndt/gfm834] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Abstract
The use of CT in the diagnosis and management of liver trauma is responsible for the shift from routine surgical versus non-surgical treatment in the management of traumatic liver injuries, even when they are of high grade. The main cause of complication and of death in liver trauma is related to vascular injury. The goal of this review focussed on the vascular complications of liver trauma is to describe the elementary lesions shown by CT in liver trauma including laceration, parenchymal hematoma and contusions, partial devascularisation, subcapsular hematomas, hemoperitoneum, active bleeding, pseudoaneurysm of the hepatic artery, bile leak, and periportal oedema, to illustrate the possible pitfalls in CT diagnosis of liver trauma and to underline the key-points which may absolutely be present in a CT report of liver trauma. Then we will remind the grading system based on the CT features and we will analyze the interest and limitations of such grading systems. Last we will discuss the diagnostic strategy at the early phase in patients with suspected liver trauma according to their clinical conditions and underline the conditions of arterial embolization, and then we will discuss the diagnosis strategy at the delayed phase according to the suspected complications.
Collapse
Affiliation(s)
- P Taourel
- Centre Hospitalier Universitaire Lapeyronie, Montpellier, France.
| | | | | | | | | | | |
Collapse
|
42
|
Felicori L, Araujo SC, de Avila RAM, Sanchez EF, Granier C, Kalapothakis E, Chávez-Olórtegui C. Functional characterization and epitope analysis of a recombinant dermonecrotic protein from Loxosceles intermedia spider. Toxicon 2006; 48:509-19. [PMID: 16934304 DOI: 10.1016/j.toxicon.2006.06.019] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2005] [Revised: 05/23/2006] [Accepted: 06/07/2006] [Indexed: 11/28/2022]
Abstract
In the present study the recombinant form (recLiD1) of a dermonecrotic protein present in the Brazilian brown spider Loxosceles intermedia venom was expressed in Escherichia coli cells and purified by reversed-phase HPLC using a C8 Vydac column. About 25.8mg of purified recLiD1 was produced from a litre of bacterial culture. SDS/PAGE and immunoblot analysis of the recombinant protein revealed an apparent molecular weight of 32-35kDa. The later result was confirmed by mass spectrometry (32,758Da). recLiD1 displayed dermonecrotic and platelet aggregation activities which were qualitatively similar to that displayed by the crude L. intermedia venom. However, very low sphingomyelinase D enzymatic activity and complement-dependent haemolytic activities were observed. recLiD1 immunized BALB/c mice developed an antibody response. Anti-recLiD1 antibodies recognized L. intermedia venom in an indirect enzyme-linked immunosorbent assay (ELISA) and cross-reacted with crude venoms from L. intermedia, L. gaucho and L. laeta. An in vivo protection assay carried out 5 weeks after the end of the immunization protocol showed that 75% of the vaccinated mice could resist the challenge by 2.5LD(50) of L. intermedia venom. To characterize epitopes associated with protective antibodies, we prepare sets of immobilized synthetic 15 mer overlapping peptides covering the complete amino acid sequences of the recLiD1. Antibodies revealed one antigenic region in the N-terminal part of the toxin. The amino acid sequence of this epitope was found in several dermonecrotic proteins and some of its residues have been implicated with the active site of the toxin.
Collapse
Affiliation(s)
- L Felicori
- Departamentos de Bioquímica-Imunologia, Universidade Federal de Minas Gerais, CEP 30161-970, Belo Horizonte, MG, Brazil
| | | | | | | | | | | | | |
Collapse
|
43
|
Ferreira RN, Machado de Avila RA, Sanchez EF, Maria WS, Molina F, Granier C, Chávez-Olórtegui C. Antibodies against synthetic epitopes inhibit the enzymatic activity of mutalysin II, a metalloproteinase from bushmaster snake venom. Toxicon 2006; 48:1098-103. [PMID: 17014879 DOI: 10.1016/j.toxicon.2006.07.040] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2006] [Revised: 07/13/2006] [Accepted: 07/19/2006] [Indexed: 11/24/2022]
Abstract
Mutalysin II (mut-II), a 22.5kDa zinc endopeptidase isolated from bushmaster (Lachesis muta muta) snake venom, is a direct acting fibrin(ogen)olytic proteinase. It induces monoclonal and polyclonal antibodies which efficiently neutralize the hemorrhagic effect of L. muta and several Bothrops whole venoms. To characterize epitopes of protective antibodies we have used the Spot method of multiple peptide synthesis to prepare 64 overlapping dodecapeptides frameshifted by three residues, covering the complete amino acid sequence of mut-II. The rabbit anti-mut-II antibodies binding pattern to peptides revealed several continuous antigenic regions: one in the N-terminal part, two in the central region and the other in the C-terminal of mut-II. By using homology modelling, a three-dimensional model of mut-II was built which showed that epitopes are surface exposed. Anti-peptide antibodies were raised against three peptides (one representative of each epitope region) covalently coupled as a mixture to keyhole limpet hemocyanin. Purified IgG from the resulting anti- peptide antibodies cross-reacted with mut-II and induced a dose-dependent inhibition of the mut-II catalyzed proteolysis of fibrinogen.
Collapse
Affiliation(s)
- R N Ferreira
- Departamento de Bioquímica e Imunologia, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | | | | | | | | | | | | |
Collapse
|
44
|
Dreux M, Peitschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL. O.171 HDL inhibits HCV neutralisation by CD81-NOB antibodies by stimulating cell entry through activation of the scavenger receptor BI. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80161-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot P, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset F. O.137 HDL inhibits neutralisation by HCV antibodies via a ternary interaction with the scavenger receptor BI. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80131-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
Alvarenga LM, Machado de Avila RA, Amim PR, Martins MS, Kalapothakis E, de Lima ME, Santos RG, Granier C, Chávez-Olórtegui C. Molecular characterization of a neutralizing murine monoclonal antibody against Tityus serrulatus scorpion venom. Toxicon 2005; 46:664-71. [PMID: 16168449 DOI: 10.1016/j.toxicon.2005.07.014] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2005] [Revised: 07/12/2005] [Accepted: 07/13/2005] [Indexed: 10/25/2022]
Abstract
Monoclonal antibodies (mAbs) against Tityus serrulatus venom were obtained by the fusion of SP2/0 murine myeloma cells and spleen cells from BALB/c mice immunized with a toxic fraction (TstFG50) of the Tityus venom (this G50 chromatography fraction represents most of the toxicity of the crude venom) conjugated to bovine serum albumin (BSA) with glutaraldehyde. From the initial screening of over 200 hybridoma fusion wells, a panel of 9 anti-TstFG50 secreting hybridomas was established. The capacity of mAbs to neutralize the TstFG50 toxic fraction toxic was determined by in vitro neutralization assays and by inhibition of the binding of 125I-TsVII to its site on rat brain synaptosomes. Only mAbTs1 neutralized 50% of the toxic effects produced by scorpion venom and showed 35% inhibition of the binding of 125I-TsVII at 10(-7) M. To map the epitope recognized by the protective mAbTs1, we prepared a comprehensive series of overlapping 15-mer synthetic peptides covering the amino acid sequences of the four Tityus proteins. MAbTs1 reacted with peptide 26 of TsIV (KKSKDKKADSGYSYW), peptide 30 of TsVII (KKGSSGYSAWPASYS) and peptide 31 of TsNTxP (KKGSSGYSAWPASYS). MAbTs1 was not reactive with any peptide from TsII. The N-terminal lysine residue from the epitope was found to be critical for mAbTs1 binding. The epitope was positioned on the available three-dimensional structure of TsVII together with the recently identified residues from the pharmacophore of beta-scorpion toxins. The neutralizing properties of mAbTs1 might be explained by spatial vicinity of epitope residues with pharmacophore residues.
Collapse
Affiliation(s)
- L M Alvarenga
- Departamentos de Bioquímica-Imunologia, ICB, Universidade Federal de Minas Gerais, CP: 486; CEP: 31270901, Belo Horizonte-MG, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Maria WS, Velarde DT, Alvarenga LM, Nguyen C, Villard S, Granier C, Chávez-Olórtegui C. Localization of epitopes in the toxins of Tityus serrulatus scorpions and neutralizing potential of therapeutic antivenoms. Toxicon 2005; 46:210-7. [PMID: 15970301 DOI: 10.1016/j.toxicon.2005.03.024] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2004] [Accepted: 03/31/2005] [Indexed: 11/21/2022]
Abstract
Overlapping pentadecapeptides covering the complete amino acid sequence of TsII, TsVII and TsIV toxins from the venom of scorpion Tityus serrulatus (Ts), were prepared by use of the Spot method of multiple peptide synthesis. Horse anti-Ts antisera for therapeutic use were tested for their binding to peptides. All nine antisera tested showed reactivity with several peptides from the three toxins. Three antigenic regions, one in the very N-terminal, the second in the central part and the other in the C-terminal part of the three toxins were frequently, but not constantly recognized, with an intensity that seemed to be related to the neutralizing potency of the tested antivenom. Thus the corresponding peptides (residues 1-15 and 48-62 of TsII; residues 1-15, 16-30 and 48-62 of TsIV and residues 1-15 and 47-61 of TsVII) were synthesized, coupled to KLH and used as antigens to coat the microtitration plates to determine any relationship between their ELISA reactivity with therapeutic horse antivenoms and the neutralizing potential of these antivenoms. The mixture of the N-terminal peptide of TsII, of the N-terminal TsVII peptide and of the C-terminal of TsIV was found to give a linear relationship with the neutralizing titer of horse serum of low neutralizing potency (< or =1 mg/ml). However, high neutralizing antivenoms did not show the expected response in peptide ELISA. This observation is discussed in the context of the occurrence of continuous and discontinuous epitopes on toxins.
Collapse
Affiliation(s)
- W S Maria
- Fundação Ezequiel Dias, Rua Conde Pereira Carneiro 80, 30550-010 Belo Horizonte, MG, Brazil
| | | | | | | | | | | | | |
Collapse
|
48
|
Plouhinec JL, Granier C, Le Mentec C, Lawson KA, Sabéran-Djoneidi D, Aghion J, Shi DL, Collignon J, Mazan S. Identification of the mammalian Not gene via a phylogenomic approach. Gene Expr Patterns 2005; 5:11-22. [PMID: 15533813 DOI: 10.1016/j.modgep.2004.06.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2004] [Accepted: 06/28/2004] [Indexed: 10/26/2022]
Abstract
Despite the great morphological diversity of early embryos, the underlying mechanisms of gastrulation are known to be broadly conserved in vertebrates. However, a number of genes characterized as fulfilling an essential function in this process in several model organisms display no clear ortholog in mammalian genomes. We have devised an in silico phylogenomic approach, based on exhaustive similarity searches in vertebrate genomes and subsequent bayesian phylogenetic analyses, to identify such missing genes, presumed to be highly divergent. This approach has been used to identify mammalian orthologs of Not, an homeodomain containing gene previously characterized in Xenopus, chick and zebrafish as playing a critical role in the formation of the notochord. This attempt led to the identification of a highly divergent mammalian Not-related gene in the mouse, human and rat. The results from phylogenetic reconstructions, synteny analyses, expression pattern analyses in wild-type and mutant mouse embryos, and overexpression experiments in Xenopus embryos converge to confirm these genes as representatives of the Not family in mammals. The identification of the mammalian Not gene delivers an important component for the understanding of the genetics underlying notochord formation in mammals and its evolution among vertebrates. The phylogenomic method used to retrieve this gene thus provides a tool, which can complement or validate genome annotations in situations when they are weakly supported.
Collapse
Affiliation(s)
- J-L Plouhinec
- Développement et Evolution des Vertébrés, UMR 8080, Université Paris-Sud, 91405 ORSAY, France
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Granier C, Brunel H, Lebars E, Bonafe A. [Clinical case #2. Cerebral gliomatosis]. J Radiol 2005; 86:516-9. [PMID: 16114212 DOI: 10.1016/s0221-0363(05)81401-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Affiliation(s)
- C Granier
- Service de Neuroradiologie, Hôpital Gui de Chauliac, 80 Avenue Augustin Fliche, 34295 Montpellier
| | | | | | | |
Collapse
|
50
|
Mendes TM, Maria WS, Granier C, Chávez-Olórtegui C, Kalapothakis E. Epitope mapping of the antigenic protein TsNTxP from Tityus serrulatus scorpion venom using mouse, rabbit and sheep antibodies. Toxicon 2005; 44:617-24. [PMID: 15501287 DOI: 10.1016/j.toxicon.2004.07.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2004] [Revised: 07/05/2004] [Accepted: 07/06/2004] [Indexed: 11/25/2022]
Abstract
In the present investigation we used native and recombinant TsNTxP to elicit antibodies in three different animal models (mouse, rabbit and sheep). Differences among anti-TsNTxP antibodies were analyzed using sets of overlapping pentadecapeptides of the TsNTxP amino acid sequence and also modified peptides to reveal key residues in antibody-peptide binding. Despite the identification of similar peptides by the antibodies in the C and N-terminal, peculiarities of each system were observed including the level of reactivity and also the number and type of key residues in the continuous epitopes of TsNTxP. In addition, in vitro neutralization assays indicated that sheep are an alternative and efficient model for the production of anti-Tityus serrulatus venom.
Collapse
Affiliation(s)
- T M Mendes
- Departamento de Biologia Geral-Genética, ICB, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627 Pampulha, 31270-901 Belo Horizonte, MG, Brazil
| | | | | | | | | |
Collapse
|